Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05186220
Other study ID # 2021/307
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date November 1, 2023

Study information

Verified date January 2022
Source Hospital Clinico Universitario de Santiago
Contact Carlos Minguito Carazo, MD
Phone 981 95 07 93
Email carlosminguito@hotmail.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Endocardial ganglion plexus ablation (cardioneuroablation) represents a promising therapeutic technique for the treatment of vasovagal syncope (VV), functional atrioventricular block (AVB) and sinus node dysfunction (SND) with a component of vagal hypertonia. Nevertheless, there is currently a paucity of literature about the results according to the type of presentation (VV, AVB or SND). The investigators aim to assess the safety and efficacy of cardioneuroablation for the treatment of symptomatic SND.


Description:

Sinus node dysfunction (SND), also known as sick sinus syndrome, comprises a wide spectrum of sinoatrial dysfunctions, ranging from sinus bradycardia, sinoatrial block, and sinus arrest to bradycardia tachycardia syndrome. An additional manifestation of SND is an inadequate chronotropic response to exercise, reported as chronotropic incompetence. Since the first cardiac denervation was reported in 2005, several registries and retrospective studies using this therapeutic approach for reflex syncope, SND and functional atrioventricular block have been published. However, due to the lack of randomized studies, current guidelines recommend permanent pacemaker implantation for patients with symptomatic SND in order to improve symptoms. Therefore, the purpose of the present study is to assess the safety and efficacy of cardioneuroablation versus permanent pacemaker implantation for the treatment of symptomatic SND. This is a multicenter, randomized, open, interventional study. After being informed of the study and potential risks, participants will undergo a one week screening period to determine eligibility for the study entry. During this week, participants will undergo an exercise test, atropine test, and a 24 hour-holter electrocardiogram. Then, participants who meet the eligibility criteria, will be randomized 1:1 to receive permanent pacemaker implantation (control group) or cardioneuroablation (interventional group). The primary endpoint (improve in quality of life assessed with 36-Item Short Form Survey (SF-36)) will be evaluated at six months since randomization.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date November 1, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Symptomatic sinus node dysfunction (dizziness, asthenia or syncope) clearly related to an abnormal electrocardiogram finding (sinus arrest, sinoatrial block, extreme bradycardia (<40 bpm) or chronotropic incompetence in the exercise test). - Absence of structural cardiopathy Exclusion Criteria: - Left ventricular ejection fraction <50% - Severe valvular disease - Any type of cardiomyopathy such as hypertrophic cardiomyopathy - Previous ischemic heart disease - QRS interval >130 ms - Atrioventricular conduction disorder with a former indication of pacemaker implantation (atrioventricular block Mobitz II, advanced atrioventricular block, complete atrioventricular block) - Lifetime expectance <12 months

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cardioneuroablation
After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
Device:
Permanent dual chamber pacemaker implantation
Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.

Locations

Country Name City State
Spain Hospital Clinico Universitario de Santiago Santiago de Compostela A Coruña

Sponsors (3)

Lead Sponsor Collaborator
Hospital Clinico Universitario de Santiago Hospital Universitario Lucus Augusti, Spanish Society of Cardiology

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Hu F, Zheng L, Liang E, Ding L, Wu L, Chen G, Fan X, Yao Y. Right anterior ganglionated plexus: The primary target of cardioneuroablation? Heart Rhythm. 2019 Oct;16(10):1545-1551. doi: 10.1016/j.hrthm.2019.07.018. Epub 2019 Jul 19. — View Citation

Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results. Europace. 2011 Sep;13(9):1231-42. doi: 10.1093/ — View Citation

Pachon-M JC, Pachon-M EI, Pachon CTC, Santillana-P TG, Lobo TJ, Pachon-M JC, Zerpa-A JC, Cunha-P MZ, Higuti C, Ortencio FA, Amarante RC, Silva RF, Osorio TG. Long-Term Evaluation of the Vagal Denervation by Cardioneuroablation Using Holter and Heart Rate Variability. Circ Arrhythm Electrophysiol. 2020 Dec;13(12):e008703. doi: 10.1161/CIRCEP.120.008703. Epub 2020 Nov 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in the SF-36 Health Survey of quality of life The SF-36 Health Survey is a validated, well known generic test for assessment of the health-related quality of life of patients. Baseline and 6 months
Secondary 6 month free survival from permanent pacemaker implantation in the interventional group (cardioneuroablation) Percentage of patients free from pacemaker at one year in the cardioneuroablation group Baseline and 6 months
Secondary Change in maximal heart rate and chronotropic incompetence in the exercise test All patients will perform a baseline exercise test and after 6 months. Maximal heart rate and chronotropic response will be recorded. Baseline and 6 months
Secondary Differences in complications rates between both gropus Most common complications regarding the procedure. In the cardioneuroablation group; complications regarding vascular access and pericardial tamponade. In the pacemaker group, pneumothorax, device infection and vascular access. Baseline and 6 months
Secondary Differences in 6 month free survival from syncope between both groups Syncope will be defined as any spontaneous loss of conscious with posterior recovery. Baseline and 6 months
See also
  Status Clinical Trial Phase
Completed NCT00286858 - Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing
Active, not recruiting NCT00228241 - Left Ventricular Function and Remodelling During Permanent Pacing N/A
Completed NCT00180557 - Austria Study - Analysis of Difference Between Active and Passive Fixation Leads Phase 4
Not yet recruiting NCT04149886 - Cardiac Ganglionated Plexus Ablation Before Permanent Pacemaker Implantation in Patients With Sick Sinus Syndrome N/A
Completed NCT01609738 - Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum Phase 1/Phase 2
Completed NCT00785564 - Imaging Cardiac Electrical Remodeling With Electrocardiogram Imaging (ECGI)
Recruiting NCT00161551 - Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Phase 4
Recruiting NCT00224341 - Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Phase 4
Recruiting NCT05575557 - Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment N/A
Completed NCT03843242 - Evaluation of Ventricular Pacing Suppression Algorithms in Dual Chamber Pacemaker N/A
Terminated NCT00475124 - Virtual Clinic Pacemaker Follow-up Phase 4
Recruiting NCT06288633 - Cardioneuroablation for Bradyarrhythmia N/A
Terminated NCT00236158 - The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome Phase 2/Phase 3
Completed NCT00000561 - Mode Selection Trial in Sinus Node Dysfunction (MOST) Phase 3
Completed NCT02154750 - AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals N/A
Completed NCT02198781 - Right Ventricle (RV) Markers of Future Pacing Induced Ventricular Dysfunction - Pilot
Recruiting NCT01477138 - RV Septal Versus Minimized RV Pacing in Sick Sinus Syndrome N/A
Terminated NCT01074749 - Optimal Sensing in Atrial Tachyarrhythmia's Study N/A
Completed NCT00627328 - The Atrial High Rate Episodes in Pacemaker Patients N/A
Completed NCT00161538 - Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation Phase 4